Latest Leadership News

Orcoda Limited reported a 26% reduction in net loss and a 23% rise in Annual Recurring Revenue, boosted by a new $8 million per annum multi-year contract with Wagner Corporation, setting the stage for SaaS expansion in FY27.

OncoSil Medical lifted revenues 44% in FY26 to $1.68 million and trimmed losses by 28% to $10.86 million, buoyed by key regulatory approvals including FDA HDE and Australian TGA listings. The company is poised for commercial launches in the US and Australia, with strong clinical data underpinning its growth.

Alterity Therapeutics posted a 285% jump in revenue to A$1.72 million but also a 93% rise in net loss to A$23.4 million for FY2026. The company secured FDA alignment on a single pivotal Phase 3 trial for ATH434 in Multiple System Atrophy, setting the stage for trial start by year-end.

RooLife Group (ASX: RLG) reported a 268% jump in FY2026 revenue to nearly $10 million, driven by rapid growth in its own food and beverage products, including RLG Coffee in China. Despite this, the company recorded a $3.58 million net loss, weighed down by impairment charges and R&D investments in renewable energy.

Elixir Energy has marked FY26 with major progress in Queensland’s Taroom Trough, expanding contingent gas resources by 32% and securing a strategic $16.6 million capital raise led by Omega Oil and Gas. The company’s operational advances and government backing position it as a key player in Australia’s energy security landscape.

Paradigm Biopharmaceuticals has surpassed its Phase 3 enrolment target for Zilosul®, secured over A$21 million in capital, and pivots towards clinical evidence generation with major data readouts expected.

HITIQ Limited posted a 21% drop in revenue to $1.59 million and reduced its net loss by 15% to $6.1 million for FY26, advancing commercialisation of its concussion management platform PROTEQT™ despite ongoing funding pressures and regulatory hurdles.

Beonic Limited has completed a three-year turnaround, reporting a profitable FY26 with EBITDA of A$4.0m and a 17.2% margin. The company’s unified spatial analytics platform and new AI product underpin FY27 growth guidance targeting ~A$20m ARR and a 19% EBITDA margin.

SPC Global reported a 27% rise in normalised EBITDA for FY26 to $38.5 million, supported by a $100 million equity raise that halved net leverage. The company’s strategic pivot to higher-margin branded products and operational efficiencies set the stage for targeted double-digit revenue and EBITDA growth in FY27.

Kyron Capital Group (ASX: KYN) reported a $51.9 million net loss for FY26, completing a $125 million recapitalisation to stabilise its balance sheet and reduce gearing. The Group's assets under management shrank to $1.8 billion following strategic divestments and mandate exits.

Mirrabooka Investments posted a 63.6% profit increase to $13 million for FY26 but saw its portfolio return lag the benchmark. The company declared a 14 cents fully franked dividend and welcomed Alison Gibson as new CEO following Mark Freeman's retirement.

Kip McGrath Education Centres reversed prior losses with a $2.5 million profit in FY26 despite a 4.3% revenue dip driven by franchise consolidation and foreign exchange headwinds. The company declared a special dividend and faces an unsolicited $0.73 per share takeover offer.